Related references
Note: Only part of the references are listed.Real-World Outcomes after 36-Month Treatment with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema (BOREAL-DME)
Pascale Massin et al.
OPHTHALMIC RESEARCH (2021)
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab Post Hoc Review of HAWK and HARRIER
Jordi Mones et al.
OPHTHALMOLOGY (2021)
Faricimab: expanding horizon beyond VEGF
Ashish Sharma et al.
EYE (2020)
Evaluation and Care of Patients with Diabetic Retinopathy
Lee M. Jampol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration The STAIRWAY Phase 2 Randomized Clinical Trial
Arshad M. Khanani et al.
JAMA OPHTHALMOLOGY (2020)
Retinal Vasculitis After Administration of Brolucizumab Resulting in Severe Loss of Visual Acuity
Srinivas Sai A. Kondapalli
JAMA OPHTHALMOLOGY (2020)
Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab
Majid Khan et al.
CELLS (2020)
Futility as the Basis for Suspending Treatment of Neovascular Age-Related Macular Degeneration: An Important but not Easily Defined Concept
Jeffrey S. Heier
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2020)
The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye
Quan Dong Nguyen et al.
INTERNATIONAL JOURNAL OF RETINA AND VITREOUS (2020)
Age-related macular degeneration: a review of current therapies and new treatments
Vinicius Kniggendorf et al.
ARQUIVOS BRASILEIROS DE OFTALMOLOGIA (2020)
Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
Eric R. Chen et al.
CLINICAL OPHTHALMOLOGY (2020)
An update on conbercept to treat wet age-related macular degeneration
L. Ferro Desideri et al.
DRUGS OF TODAY (2020)
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema BOULEVARD Phase 2 Randomized Trial
Jayashree Sahni et al.
OPHTHALMOLOGY (2019)
Analysis of a Systematic Review About Blue Light-Filtering Intraocular Lenses for Retinal Protection: Understanding the Limitations of the Evidence
Laura E. Downie et al.
JAMA OPHTHALMOLOGY (2019)
Efficacy of simultaneous VEGF-A/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization
Richard H. Foxton et al.
EMBO MOLECULAR MEDICINE (2019)
Diabetic Retinopathy in the Context of Patients with Diabetes
Olga Simo-Servat et al.
OPHTHALMIC RESEARCH (2019)
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration Results from the Randomized Phase 2 Ladder Clinical Trial
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2019)
Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration
Lorenzo Ferro Desideri et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Innovative therapies for neovascular age-related macular degeneration
Hasenin Al-Khersan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease
Rehan M. Hussain et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks
Sankha Amarakoon et al.
ACTA OPHTHALMOLOGICA (2019)
A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema
Ye He et al.
BMC OPHTHALMOLOGY (2018)
Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
Charles C. Wykoff et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
Age-related macular degeneration
Paul Mitchell et al.
LANCET (2018)
Diabetic macular edema: Evidence-based management
David J. Browning et al.
INDIAN JOURNAL OF OPHTHALMOLOGY (2018)
Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGICA (2017)
Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration
Usha Chakravarthy et al.
OPHTHALMOLOGY RETINA (2017)
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
Joerg T. Regula et al.
EMBO MOLECULAR MEDICINE (2016)
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial
John A. Wells et al.
OPHTHALMOLOGY (2016)
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
John A. Wells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Molecular pathogenesis of retinal and choroidal vascular diseases
Peter A. Campochiaro
PROGRESS IN RETINAL AND EYE RESEARCH (2015)
Comparing aflibercept, bevacizumab, and ranibizumab for DME: Analysis of DRCR Protocol T
Charles C. Wykoff et al.
OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2015)
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
Wan Ling Wong et al.
LANCET GLOBAL HEALTH (2014)
Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFβ1 in diabetic eyes undergoing vitrectomy
Sirpa Loukovaara et al.
ACTA OPHTHALMOLOGICA (2013)
Angiopoietin-2 Is Critical for Cytokine-Induced Vascular Leakage
Andrew V. Benest et al.
PLOS ONE (2013)
Age-related macular degeneration
Laurence S. Lim et al.
LANCET (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system
Hellmut G. Augustin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Different effects of angiopoietin-2 in different vascular beds in the eye: new vessels are most sensitive
Y Oshima et al.
FASEB JOURNAL (2005)
Ocular perfusion abnormalities in diabetes
TA Ciulla et al.
ACTA OPHTHALMOLOGICA SCANDINAVICA (2002)
Share Paper
